Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations

Respiratory Medicine

Volumn 108, Issue 8, 2014, Pages 1153-1162

  Wedzicha, J A ^a   Singh, D ^b   Vestbo, J ^d   Paggiaro, P L ^c   Jones, P W ^e   Bonnet Gonod, F ^f   Cohuet, G ^f   Corradi, M ^g   Vezzoli, S ^h   Petruzzelli, S ^h   Agusti, A ⁱ  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY HOSPITAL OF PISA   (Italy)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^f Chiesi   (France)

^g UNIVERSITY OF PARMA   (Italy)

^h CHIESI FARMACEUTICI S P A   (Italy)

ⁱ HOSPITAL CLÍNIC   (Spain)

Author keywords

COPD; Exacerbation; Extrafine; Inhaled steroids; Long acting bronchodilators; Patient reported outcomes

Indexed keywords

BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE; FORMOTEROL FUMARATE; SALBUTAMOL; THEOPHYLLINE; TIOTROPIUM BROMIDE; BECLOMETASONE; BRONCHODILATING AGENT; ETHANOLAMINE DERIVATIVE; FORMOTEROL; GLUCOCORTICOID;

ADULT; ARTHRALGIA; ARTICLE; BACKACHE; BREAST DISEASE; BRONCHOPNEUMONIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONSTIPATION; COUGHING; DERMATITIS; DIARRHEA; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; GASTRITIS; GASTROENTERITIS; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; INFLUENZA; INSOMNIA; LOBAR PNEUMONIA; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUSCLE SPASM; NAUSEA; PERIPHERAL EDEMA; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINUSITIS; ST. GEORGE RESPIRATORY QUESTIONNAIRE; THORAX PAIN; THRUSH; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECTS; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEASON; TREATMENT OUTCOME; VITAL CAPACITY;

BECLOMETHASONE; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEASONS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84906322078     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2014.05.013     Document Type: Article

References (30)

1. The global burden of disease, 2004 update, World Health Organization. ISBN 978 92 4 156371 0. http://www.who.int/healthinfo/global-burden-disease/GBD- report-2004update-full.pdf.
2. G.C. Donaldson, T.A.R. Seemungal, A. Bhowmik, and J.A. Wedzicha Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease Thorax 57 2002 847 852
3. A. De Backer W,Devolder, G. Poli, D. Acerbi, R. Monno, C. Herpich, K. Sommerer, T. Meyer, and F. Mariotti Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients J Aerosol Med Pulm Drug Deliv 23 2010 137 148
4. P.M. Calverley, P. Kuna, E. Monsó, M. Costantini, S. Petruzzelli, F. Sergio, G. Varoli, A. Papi, and V. Brusasco Beclomethasone/formoterol in the management of COPD: a randomised controlled trial Respir Med 104 12 2010 Dec 1858 1868
5. D. Singh, J. Kampschulte, J.A. Wedzicha, P.W. Jones, G. Cohuet, M. Corradi, T. Higenbottam, S. Petruzzelli, and J. Vestbo A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbations Eur Respir J 41 1 2013 Jan 12 17
6. J.R. Hurst, J. Vestbo, A. Anzueto, N. Locantore, H. Müllerova, R. Tal-Singer, B. Miller, D.A. Lomas, A. Agusti, W. MacNee, P. Calverley, S. Rennard, E.F.M. Wouters, J.A. Wedzicha Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators Susceptibility to exacerbation in chronic obstructive pulmonary disease N Engl J Med 363 2010 1128 1138
7. T.A. Seemungal, G.C. Donaldson, E.A. Paul, J.C. Bestall, D.J. Jeffries, and J.A. Wedzicha Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 157 5 Pt 1 1998 May 1418 1422
8. T.M. Wilkinson, G.C. Donaldson, J.R. Hurst, T.A. Seemungal, and J.A. Wedzicha Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease Am J Respir Crit Care Med 169 12 2004 Jun 15 1298 1303 [Epub 2004 Feb 27]
9. L. Langsetmo, R.W. Platt, P. Ernst, and J. Bourbeau Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort Am J Respir Crit Care Med 177 4 2008 Feb 15 396 401
10. N.K. Leidy, T.K. Wilcox, P.W. Jones, L. Roberts, J.H. Powers, S. Sethi EXACT-PRO Study Group Standardizing measurement of chronic obstructive pulmonary disease exacerbations. Reliability and validity of a patient-reported diary Am J Respir Crit Care Med 183 3 2011 Feb 1 323 329
11. J. Vestbo, S.S. Hurd, A.G. Agustí, P.W. Jones, C. Vogelmeier, A. Anzueto, P.J. Barnes, L.M. Fabbri, F.J. Martinez, M. Nishimura, R.A. Stockley, D.D. Sin, and R. Rodriguez-Roisin Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary Am J Respir Crit Care Med 187 4 2013 Feb 15 347 365
12. M.R. Miller, J. Hankinson, V. Brusasco, F. Burgos, R. Casaburi, A. Coates, R. Crapo, P. Enright, C.P. van der Grinten, P. Gustafsson, R. Jensen, D.C. Johnson, N. MacIntyre, R. McKay, D. Navajas, O.F. Pedersen, R. Pellegrino, G. Viegi, J. Wanger ATS/ERS Task Force Standardisation of spirometry Eur Respir J 26 2 2005 Aug 319 338
13. P.W. Jones, F.H. Quirk, and C.M. Baveystock The St. George's respiratory questionnaire Respir Med 85 Suppl. B 1991 Sep 25 31
14. O.N. Keene, P.M. Calverley, P.W. Jones, J. Vestbo, and J.A. Anderson Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited ERJ 32 1 July 1, 2008 17 24
15. L.J. Nannini, T.J. Lasserson, and P. Poole Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease Cochrane Database Syst Rev 9 2012 Sep 12
16. D.A. Mahler, P. Wire, and D. Horstman Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease Am J Respir Crit Care Med 116 2002 1084 1091
17. D.E. Doherty, D.P. Tashkin, E. Kerwin, B.A. Knorr, T. Shekar, B. Banerjee, and H. Staudinger Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week phase III trial in subjects with moderate-to-very severe COPD Int J Chron Obstruct Pulmon Dis 7 2012 57 71
18. S.I. Rennard, D.P. Tashkin, J. McElhattan, M. Goldman, S. Ramachandran, U.J. Martin, and P.E. Silkoff Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease Drugs 69 5 2009 March 549 565
19. Ito K1, S. Lim, G. Caramori, K.F. Chung, P.J. Barnes, and I.M. Adcock Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages FASEB J 15 6 2001 Apr 1110 1112
20. S. Spencer, P.M. Calverley, P.S. Burge, and P.W. Jones Impact of preventing exacerbations on deterioration of health status in COPD Eur Respir J 23 5 2004 May 698 702
21. S. Sethi, P.W. Jones, M. Schmitt Theron, E. Miravitlles, E. Rubinstein, J.A. Wedzicha, and R. Wilson Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial Respir Res 11 2010 10
22. G.T. Ferguson, A. Anzueto, R. Fei, A. Emmett, K. Knobil, and C. Kalberg Effect of fluticasone propionate/salmeterol (250/50 μg) or salmeterol (50 μg) on COPD exacerbations Respir Med 102 8 2008 Aug 1099 1108
23. J.A. Wedzicha, P.M.A. Calverley, T.A. Seemungal, G. Hagan, A. Ansari, and R.A. Stockley The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide Am J Respir Crit Care Med 177 2008 19 26
24. G.C. Donaldson, J.J. Goldring, and J.A. Wedzicha Influence of season on exacerbation characteristics in patients with COPD Chest 141 1 2012 Jan 94 100
25. J.A. Wedzicha, and G.C. Donaldson Exacerbations of chronic pulmonary disease Respir Care 48 12 2003 Dec 1204 1213
26. N.W. Johnston, K. Lambert, P. Hussack, M. Gerhardsson de Verdier, T. Higenbottam, J. Lewis, P. Newbold, M. Jenkins, G.R. Norman, P.V. Coyle, and R.A. McIvor Detection of COPD exacerbations and compliance with patient-reported daily symptom diaries Chest 144 2 2013 Aug 507 514 10.1378/chest.12-2308
27. T. Seemungal, R. Harper-Owen, A. Bhowmik, I. Moric, G. Sanderson, S. Message, P. MacCallum, T.W. Meade, D.J. Jeffries, S.L. Johnston, and J.A. Wedzicha Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease Am J Respir Crit Care Med Vol. 164 2001 1618 1623
28. P. Kardos, M. Wencker, T. Glaab, and C. Vogelmeier Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease Am J Respir Crit Care Med 175 2 2007 Jan 15 144 149
29. A. Anzueto, G.T. Ferguson, G. Feldman, K. Chinsky, A. Seibert, A. Emmett, K. Knobil, D. O'Dell, C. Kalberg, and G. Crater Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes COPD 6 5 2009 Oct 320 329
30. A. Sharafkhaneh, J.G. Southard, M. Goldman, T. Uryniak, and U.J. Martin Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study Respir Med 106 2 2012 Feb 257 268